Enzon Pharmaceuticals, Inc. is selling 25% interest in its royalty from PEG-INTRON, marketed by Schering-Plough Corp. for $92.5 million to Drug Royalty Corp., Inc. (DRC). Enzon is also eligible to receive an additional one-time milestone payment of $15 million in 2012 if certain royalty recognition levels are met for PEG-INTRON. Enzon will retain a 75% interest in the PEG-INTRON royalty, as well as 100% of their other current royalties and any new royalties the company receives. Enzon plans to u...